Please login to the form below

Not currently logged in
Email:
Password:

Immatics

This page shows the latest Immatics news and features for those working in and with pharma, biotech and healthcare.

Roche pays $1bn-plus for stake in genomics specialist

Roche pays $1bn-plus for stake in genomics specialist

In 2013 Roche licensed a series of early-stage cancer immunotherapy programmes from German company Immatics in a deal valued at more than $1bn, and promised up to $422.5m to

Latest news

More from news
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    Also, hot off the block was Amgen with the purchase of Immatics' next-generation, T-cell engaging bispecific immunotherapies. ... Immatics. Amgen. Licence / joint development. Next-generation, T-cell engaging bispecific immuno-therapies .

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    hyperactivity disorder, pain, urology and allergy. 1, 600. immatics / Roche.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics